*All times listed are Central European Time (CET)

8:00 am Registration and Coffee

8:45 am Chair’s Opening Remarks

9:00 am Presentation from Our Partners at ABX-CRO and Oncodesign Taking Radiopharmaceuticals to their Next Evolutionary Level

9:55 am Presentation from our Partners at Radiopharm Theranostics


10:25 am Speed Networking & Refreshment Break

Drug Development

Drug Discovery & Radiopharmaceutical Innovation

11:30 am Pancreatic Cancer – Can We Overcome The Status Quo?


• Epidemiology and current state-of-the-art technology
• Towards personalised and accurate diagnostics of PDAC
• Status of radiotheranostic approach – from bench to bedside

12:00 pm New Life for Satoreotide – The Antagonist Moves On

  • Manfred Rüdiger Chief Executive Officer & Managing Director, Ariceum Therapeutics


• Update regarding satoreotide
• Antagonist vs agonist, SST2 receptor
• Neuroendocrine tumors

Advanced Preclinical Practices & Technology

1:30 pm Diagnostic Radioimmunocionjugate Targeting the Oxidized Macrophage Migration Inhibitory Factor (oxMIF)


• Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine consisting of three identical
subunits that drives tumorigenic cell signaling and exerts immunomodulatory activities in the tumor

• ON102 is a radioimmunoconjugate designed to provide a non-invasive approach for diagnostic applications

Phase 1 Development

2:00 pm Phase 1 Development of Radspherin


• Radspherin®, is a new alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities
• Radspherin® has in animal models been shown to cause a reduction in tumour cell growth and a significant increased survival

Supply Chain, Infrastructure & Logistics

Radionuclide Generation & Stock Levels

11:30 am Presentation from our Partners at NRG – Field Lab


11:45 am Production & Availability of 211At: Near Term Steps Towards Global Access

  • Michael Zalutsky Professor of Radiology & Director, Radiopharmaceutical Chemistry Laboratory, Duke University


• Current Status of 211At production and availability
• Future prospects for 211At
• Discussion of feasibility of commerically-compatible supply – any time soon?

12:15 pm Presentation from our Partners at Ionetix


Radionuclide Supply Chain Hurdles & Solutions

1:30 pm Building a Resilient Isotope Supply Chain for Clinical Trials


• Building a global clinical and isotope supply
• Effectively setting up clinical sites setup
• Building a nuclear regulatory strategy

2:00 pm Alpha Targeted Therapy & Environmental Impacts

  • Jean-François Gestin Head of Chemistry & Radiochemistry, Inserm Lille Neuroscience & Cognition Research Centre


• Alpha candidate and future needs
• Production situation
• Understanding and preparing for environmental impacts

2:30 pm Afternoon Coffee Break – Poster Session

Overcoming Clinical & Radioactive Compound Regulation

3:30 pm Panel Discussion: Perspectives on the State of EU & US Radiopharmaceutical Regulation


Panel of Industry Regulatory Staff, Clinicians, Radiopharmacists, Technologists and Regulatory Consultants to discuss how EU regulation has changed over the past year and what changes they are expecting in the coming 12 months:
• EMA regulation of radiopharmaceuticals and country-specific differences in radiopharmaceutical regulation
• Ripple effects from the FDA marketing approval of Pluvitco
• What can we educate the regulators on to help reform policy on RLT in the EU?

4:15 pm End of Day One